Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label dostarlimab monotherapy in untreated dMMR/MSI-H locally advanced rectal cancer
NL-OMON56158Phase 2Recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in rectal cancer, sponsored by GSK. Primary endpoint: cCR12 by independent central review. Started Aug 2023; status: recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NL-OMON56158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56158.